Phase III trial of mipomersen in heterozygous FH

Nature Reviews Cardiology

Volumn 9, Issue 12, 2012, Pages 674-

  Mearns, Bryony M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; PLACEBO;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; DRUG MEGADOSE; DRUG SAFETY; DRUG SELF ADMINISTRATION; FAMILIAL HYPERCHOLESTEROLEMIA; HETEROZYGOTE; HUMAN; INJECTION SITE REACTION; LIVER FATTY DEGENERATION; LOW FAT DIET; NOTE; PRIORITY JOURNAL; SEX DIFFERENCE; SIDE EFFECT;

EID: 84870245894     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2012.151     Document Type: Note

References (1)

1. Stein, E. A. et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation doi:10.1161/CIRCULATIONAHA.112.104125